External Evaluations

Sustainability Evaluations

Acquired Accreditation Mark Based on the Act on Advancement of Measures to Support Raising Next-Generation Children

The Act on Advancement of Measures to Support Raising Next-Generation Children came into effect in 2005. In accordance with this law, companies that formulate action plans to support child-rearing by employees, achieve planned targets, and meet certain standards are eligible for certification by the Ministry of Health, Labour and Welfare. The Company has been certified for six consecutive years since 2007. Among companies that had already been “Kurumin” certified, Mitsubishi Tanabe Pharma was “Platinum Kurumin” certified in July 2019.

Acquired “Eruboshi” Certification Mark

In accordance with the Act on Promotion of Women’s Participation and Advancement in the Workplace, which came into effect in 2016, companies that formulate action plans to promote active careers for female employees and achieve excellent results with related initiatives are eligible for certification by the Ministry of Health, Labour and Welfare. The Eruboshi mark demonstrates that a company has received this certification. In 2016, we received “Eruboshi,” the highest level of certification, which is based on the Act on Promotion of Women’s Participation and Advancement in the Workplace.

Selected as “Outstanding Enterprise in Health and Productivity Management - White 500” for the Eighth Consecutive Year

The “Outstanding Enterprise in Health and Productivity Management Certification System,” which was established by the Ministry of Economy, Trade and Industry (METI) in 2016, is a system for recognizing companies and groups that are implementing especially strong health and productivity management. The top 500 corporations among “Outstanding Enterprises in Health and Productivity Management Certification System” (Large Corporation category) have been recognized as White 500. Mitsubishi Tanabe Pharma has been selected for eight consecutive years since 2017.

Received the Gold Prize in the PRIDE INDEX for LGBT Issues for the Fifth Consecutive Year

The PRIDE INDEX, established by the “work with Pride” association is Japan’s first index that evaluates the initiatives of companies and organizations related to sexual minorities such as LGBTs. Mitsubishi Tanabe Pharma received the GOLD Prize, the top award in the PRIDE INDEX 2023.

Recognized as a “2023 Cancer Control Promotion Excellent Company”

We were selected for four consecutive years under the Action Plan for the Promotion of Cancer Control, a project commissioned by the Ministry of Health, Labour and Welfare, for recognition and commendation as a “2022 Cancer Control Promotion Excellent Company” for our cancer prevention efforts on behalf of employees.

Recognized as a “Sports Yell Company” by the Japan Sports Agency for the Fifth Consecutive Year

The Japan Sports Agency recognizes companies that actively promote sporting activities to improve the health of their employees as a “Sports Yell Company.” This marks five consecutive years since fiscal 2020 that we have been so recognized.

Product and Technology Evaluations

Received the 2023 Breakthrough Award of the Division of Medicinal Chemistry, Pharmaceutical Society of Japan (PSJ)

In November 2023, we received the Breakthrough Award of the Division of Medicinal Chemistry, Pharmaceutical Society of Japan (PSJ) for our creation of “MC1R agonist MT-7117 (dersimeglon phosphoric acid).”
This marks the third time we have won this award, following on from our creation of “Teneligliptin” in fiscal 2013 and “Evocalcet” in fiscal 2019.
In fiscal 2023, our research focused on medical chemistry, leading to the creation of MT-7117, and the preclinical evaluation and clinical trial results for this compound were extremely well received.
The Pharmaceutical Society of Japan confers the Breakthrough Award in the Division of Medicinal Chemistry on high-level, original drug discovery research efforts, with up to two awards made yearly.

This website uses cookies to provide better content. By browsing this site, you accept our use of cookies.
Privacy Policy